Crystal structure of pirfenidone (5-methyl-1-phenyl-1H-pyridin-2-one): an active pharmaceutical ingredient (API)
The crystal structure of pirfenidone, C12H11NO [alternative name: 5-methyl-1-phenylpyridin-2(1H)-one], an active pharmaceutical ingredient (API) approved in Europe and Japan for the treatment of Idiopathic pulmonary fibrosis (IPF), is reported here for the first time. It was crystallized from toluen...
Main Authors: | Mauro Barbero, Matteo Mossotti, Angelo Sironi, Giovanni Battista Giovenzana, Valentina Colombo |
---|---|
Format: | Article |
Language: | English |
Published: |
International Union of Crystallography
2019-07-01
|
Series: | Acta Crystallographica Section E: Crystallographic Communications |
Subjects: | |
Online Access: | http://scripts.iucr.org/cgi-bin/paper?S2056989019006418 |
Similar Items
-
Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis
by: Gareth Hughes, et al.
Published: (2016-09-01) -
Pirfenidone improves survival in IPF: results from a real-life study
by: George A. Margaritopoulos, et al.
Published: (2018-11-01) -
Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy
by: Yusuke Kurita, et al.
Published: (2017-06-01) -
Idiopathic pulmonary fibrosis: Physicians' perceptions of patient treatment with recently approved drugs
by: Céline Audibert, et al.
Published: (2016-08-01) -
Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation
by: Tuong N. Vu, et al.
Published: (2019-09-01)